Navidea Biopharmaceuticals, Inc.
Gallium-68 labeled tilmanocept, a radiopharmaceutical PET imaging agent for detecting inflammatory atherosclerotic plaques
- Sector
- Medtech
- Total capital
- $14M
- Federal grants
- $14M
- 18 awards · 2015–2019
- Rank in peer group#1 of 41
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 28 pending · first 2016
- Rank in peer group#3 of 41
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques$225K
- Federal grantHealth and Human S · Phase II · CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$602K
- Federal grantHealth and Human S · Phase II · CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$940K
- Federal grantHealth and Human S · Phase II · Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$867K
- Federal grantHealth and Human S · Phase II · 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$374K
- Federal grantHealth and Human S · Phase II · CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$688K
- Federal grantHealth and Human S · Phase II · Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With mTc Tilmanocept$1.5M
Show 11 earlier federal awards
- Federal grantHealth and Human S · Phase II · Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$633K
- Federal grantHealth and Human S · Phase II · mTc Tilmanocept for Targeting Rheumatoid Arthritis RA Driving Macrophages$1.5M
- Federal grantHealth and Human S · Phase II · 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$1.1M
- Federal grantHealth and Human S · Phase II · CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$232K
- Federal grantHealth and Human S · Phase II · CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$1.2M
- Federal grantHealth and Human S · Phase II · Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$300K
- Federal grantHealth and Human S · Phase I · 99mTc-Tilmanocept Targeting of Cardiovascular Plaque in HIV Subjects$322K
- Federal grantHealth and Human S · Phase II · 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$225K
- Federal grantHealth and Human S · Phase II · [18F]NAV4694 Imaging to Identify MCI Patients at Risk for Alzheimer's Dementia$775K
- Federal grantHealth and Human S · Phase II · Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology$944K
- Federal grantHealth and Human S · Phase II · 99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 41 peers
Line = medianMedtech · Molecule
- Federal grants#1 · top 2%
- Granted patents#3 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 12 granted of 40- GrantedSynthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans And Derivatives ThereofUSPTOUS 12,583,945
- GrantedAmide Linkages Of Sugar Moieties To Amine Terminated Leashes Attached To Carbohydrate PolymersUSPTOUS 12,404,349
- GrantedCD206 Targeted Drug Delivery Vehicles Carrying Novel Bisphosphonate Drug Payloads Via A Degradable LinkerUSPTOUS 12,297,222
Show all 40 patent records
- Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans And Derivatives ThereofMar 24, 2026 · US 12,583,945Granted
- Amide Linkages Of Sugar Moieties To Amine Terminated Leashes Attached To Carbohydrate PolymersSep 2, 2025 · US 12,404,349Granted
- CD206 Targeted Drug Delivery Vehicles Carrying Novel Bisphosphonate Drug Payloads Via A Degradable LinkerMay 13, 2025 · US 12,297,222Granted
- Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive BlockingDec 31, 2024 · US 12,178,829Granted
- CD206 Targeted Drug Delivery Vehicles Carrying Novel Bisphosphonate Drug Payloads Via A Degradable LinkerJun 11, 2024 · US 12,006,339Granted
- Compounds And Methods For Diagnosis And Treatment Of Viral InfectionsJun 11, 2024 · US 12,005,122Granted
- Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans And Derivatives ThereofJan 2, 2024 · US 11,859,023Granted
- Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive BlockingDec 5, 2023 · US 11,833,170Granted
- Compositions And Methods For Altering Macrophage PhenotypeJul 13, 2023 · Application 18174783Pending
- Compositions And Methods For The Treatment Of Rheumatoid ArthritisMar 9, 2023 · Application 17891450Pending
- Compositions And Methods For Altering Macrophage PhenotypeFeb 28, 2023 · US 11,590,236Granted
- Compounds And Compositions For Treating Leishmaniasis And Methods Of Diagnosis And Treating Using SameJun 28, 2022 · US 11,369,680Granted
- Compounds And Methods For Diagnosis And Treatment Of Viral InfectionsMay 18, 2021 · US 11,007,272Granted
- Compositions And Related Methods For The Ablation Of M2 Macrophages And Myeloid Derived Suppressor CellsFeb 25, 2021 · Application 16997648Pending
- Compositions And Methods For Assessing Macrophage Mediated PathologyJul 30, 2020 · Application 16773512Pending
- CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in HumansJan 24, 2019 · Application 15984282Pending
- Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventionsJan 24, 2019 · Application 16041673Pending
- Formulations For 2-HETEROARYL Substituted BenzofuransDec 6, 2018 · Application 15777640Pending
- Compositions For Radiolabeling Diethylenetriaminepentaacetic Acid (dtpa)-dextranSep 13, 2016 · US 9,439,985Granted
- Compounds And Compositions For Targeting Macrophages And Other Mannose-binding C-type Lectin Receptor High Expressing Cells And Methods Of Treating And Diagnosis Using SameJul 21, 2016 · Application 14803010Pending
- Labeled PE2I Formulation And MethodMar 20, 2014 · Application 14026366Pending
- Tilmanocept Uptake ValueApplication 62796879Pending
- Use Of 99MTC-TILMANOCEPT And Related Molecular Constructs For Identifying And Diagnosing Malignant Tumors And For Monitoring Therapeutic Anti-tumor InterventionsApplication PCTUS2018043176Pending
- CD206+ Macrophage-specific Molecular Imaging Probe Compositions And Methods And The Noninvasive Quantification Of Arterial Wall Macrophage Infiltration In HumansApplication PCTUS2018033545Pending
- Compounds And Methods For Diagnosis And Treatment Of Viral InfectionsApplication PCTUS2017055999Pending
- Compounds And Compositions For Treating Leishmaniasis And Methods Of Diagnosis And Treating Using SameApplication PCTUS2017055998Pending
- Use of 99mTc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventionsApplication 62535752Pending
- CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in HumansApplication 62509010Pending
- Formulations For 2-HETEROARYL Substituted BenzofuransApplication PCTUS2016063154Pending
- Formulations For 2-HETEROARYL Substituted BenzofuransApplication 62258326Pending
- Compounds And Compositions For Targeting Macrophages And Other Mannose-binding C-type Lectin Receptor High Expressing Cells And Methods Of Treating And Diagnosis Using SameApplication PCTUS2015041009Pending
- Compounds And Compositions For Targeting Macrophages And Other Mannose-binding C-type Lectin Receptor High Expressing Cells And Methods Of Treating And Diagnosis Using SameApplication PCTUS2015041036Pending
- Compounds And Compositions For Targeting Macrophages And Other CD206 High Expressing Cells And Methods Of Treating And Diagnosis Using SameApplication PCTUS2015041019Pending
- Processes For Preparation Of 2-HETEROARYL Substituted Benzofuranes And Related IntermediatesApplication 62258309Pending
- Amide Linkages Of Sugar Moieties To Amine Terminated Leashes Attached To Carbohydrate PolymersApplication PCTUS2023075835Pending
- Mannosylated Amine Dextran Drug Delivery Vehicles With Degradable Disulfide/carbonate Linkers Targeting Payloads To CD206 Expressing CellsApplication PCTUS2023027630Pending
- CD206 Targeted Drug Delivery Vehicles Carrying Novel Bisphosphonate Drug Payloads Via A Degradable LinkerApplication PCTUS2023022859Pending
- Competitive Self-blocking With Unlabeled Manocept Imaging AgentsApplication PCTUS2023064936Pending
- Altering Net Charge On Mannosylated Dextrans To Maximize Target Tissue Uptake And Off Target Competitive BlockingApplication PCTUS2023061961Pending
- Methods For The Conjugation Of Anthracyclines To Carbohydrate Polymeric CarriersApplication PCTUS2022054251Pending
Related companies, and why
- DASISIMULATIONS LLCSimilar federal contract value in Medtech · null in contracts
- TREYSTA MEDICAL TECHNOLOGIES INCSimilar federal contract value in Medtech · null in contracts
- QUARKSEN LLCSimilar federal contract value in Medtech · null in contracts
- VASOWATCH LLCSimilar federal contract value in Medtech · null in contracts
- PLx Pharma Inc.Similar federal contract value in Medtech · null in contracts
- ARC Bio, LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .